CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
Blood Adv
.
2022 Aug 23;6(16):4715-4718.
doi: 10.1182/bloodadvances.2022007572.
Authors
Khushnuma Mullanfiroze
1
,
Arina Lazareva
1
,
Jan Chu
1
,
Lindsey Williams
1
,
Saskia Burridge
1
,
Juliana Silva
1
,
Robert Chiesa
1
,
Kanchan Rao
1
,
Giovanna Lucchini
1
,
Sara Ghorashian
2
,
Maeve O'Reilly
3
,
Ben Carpenter
3
,
Victoria Grandage
3
,
Rachael Hough
3
,
Claire Roddie
3
,
Persis J Amrolia
1
Affiliations
1
Department of Blood and Marrow Transplant, and.
2
Department of Haematology, Great Ormond Street Hospital, London, United Kingdom; and.
3
Department of Haematology, University College London Hospitals, London, United Kingdom.
PMID:
35790110
PMCID:
PMC9631677
DOI:
10.1182/bloodadvances.2022007572
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Antigens, CD34
Immunotherapy, Adoptive* / adverse effects
Stem Cells*
Transplantation, Homologous
Substances
Antigens, CD34